2016
DOI: 10.1111/vco.12175
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic impact of neoadjuvant aglepristone treatment in clinicopathological parameters of progesterone receptor‐positive canine mammary carcinomas

Abstract: Neoadjuvant treatment of canine mammary carcinomas with the progesterone receptor (PR) antagonist aglepristone has a PR expression-related inhibiting effect on proliferation index (PI). The aim of this study was to evaluate the effect of the treatment in the disease-free period (DFP) and overall survival (OS) of canine mammary carcinomas. Fifty female dogs with mammary carcinomas were treated with aglepristone (n = 34) or oil vehicle (n = 16) before surgery (day 15). PR expression and PI were analysed by immun… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 14 publications
(7 citation statements)
references
References 32 publications
0
7
0
Order By: Relevance
“…These apparent antiproliferative and/or pro-apoptotic activities of antigestagens in P4 responsive tissues might be responsible for the positive effects of the use of mifepristone in adjuvant therapy of some human disorders, e.g., breast cancer and endometriosis [ 50 , 51 ]. Accordingly, in dogs, positive effects of aglepristone in the clinical management of vaginal tumors and mammary carcinomas were reported, e.g., by decreasing their size [ 52 , 53 , 54 ]. Thus, in the placenta, a decreased viability of decidual cells, associated with the modulation of PCNA and a-CASP3, and disruption of cellular adhesion, as suggested by decreased expression of CX43, might represent important mechanisms in the antigestagen-induced termination of pregnancy.…”
Section: Discussionmentioning
confidence: 99%
“…These apparent antiproliferative and/or pro-apoptotic activities of antigestagens in P4 responsive tissues might be responsible for the positive effects of the use of mifepristone in adjuvant therapy of some human disorders, e.g., breast cancer and endometriosis [ 50 , 51 ]. Accordingly, in dogs, positive effects of aglepristone in the clinical management of vaginal tumors and mammary carcinomas were reported, e.g., by decreasing their size [ 52 , 53 , 54 ]. Thus, in the placenta, a decreased viability of decidual cells, associated with the modulation of PCNA and a-CASP3, and disruption of cellular adhesion, as suggested by decreased expression of CX43, might represent important mechanisms in the antigestagen-induced termination of pregnancy.…”
Section: Discussionmentioning
confidence: 99%
“…Canine mammary tumours have been suggested as a potential suitable model for studies in human breast cancer research due to the great number of similarities between them . Both human and canine mammary gland are hormone dependent; that is, they are strongly influenced by ovarian hormones, mainly oestrogen (E) and progesterone (P), which act through binding to its E receptor (ER) and P receptor (PR), respectively, and they are traditional prognostic and predictive factors in both species …”
Section: Introductionmentioning
confidence: 99%
“…The potential predictive value of immunohistochemical PR receptor determination in canine mammary carcinomas was demonstrated in studies of the PR antagonist aglepristone. A neoadjuvant aglepristone treatment increased the disease-free period in animals with tumors expressing the PR receptor [27]. Experimental studies on receptor expression in neoplastic tissues were also performed in animal species other than dogs.…”
Section: Discussionmentioning
confidence: 99%